What Is Macular Degeneration?
Age-related macular degeneration (AMD) is a progressive disease of the macula, the small central area of the retina responsible for sharp, detailed vision. The macula is what you use to read, drive, recognize faces, and see fine detail. When the macula is damaged by AMD, central vision gradually or suddenly deteriorates while peripheral (side) vision remains intact.
AMD affects approximately 19.8 million Americans aged 40 and older and is the leading cause of irreversible blindness in adults over 50 in the developed world. It exists in two forms — dry and wet — which differ dramatically in how they progress and how they are treated.
Types and Stages of AMD
Dry AMD
Dry AMD accounts for 85–90% of all cases. It develops when small yellow deposits called drusen accumulate beneath the retina and the retinal pigment epithelium (RPE) — the support layer that nourishes the retina’s light-sensing cells — begins to thin. Dry AMD progresses through stages:
- Early AMD: Small to medium drusen with no pigment changes. Usually no symptoms. The 5-year risk of progressing to late AMD is approximately 3%.
- Intermediate AMD: Large drusen or pigment changes in the macula. This is the pivotal stage — the 5-year progression risk rises to 12–50% depending on severity, and AREDS2 vitamin supplementation is recommended.
- Late Dry AMD (Geographic Atrophy): Areas of RPE and photoreceptor loss in the macula. Approximately 30% of patients with dry AMD progress to geographic atrophy. Vision loss is gradual but permanent. Two newly FDA-approved treatments can now slow this progression for the first time.
Wet AMD (Neovascular AMD)
Wet AMD accounts for only 10–15% of cases but is responsible for approximately 90% of severe vision loss from AMD. It occurs when abnormal blood vessels grow beneath the retina (choroidal neovascularization). These vessels are fragile and leak fluid and blood, causing rapid damage to the macula — sometimes within weeks. Dry AMD can convert to wet AMD at any stage, which is why regular monitoring matters even when you have “only” the dry form.
Common Symptoms
In its earliest stages, AMD often has no noticeable symptoms. It is frequently discovered during a routine dilated eye exam. As the disease progresses, you may notice:
- Subtle blurring or haziness in your central vision.
- Increased need for bright light when reading.
- Difficulty adjusting from bright to dim environments.
- Colors appearing less vivid or washed out.
- A blurry, gray, or dark area in the center of your vision (in geographic atrophy).
Symptoms that require immediate evaluation: Sudden onset of wavy or distorted lines (metamorphopsia), a new dark spot in your central vision, or rapid worsening of central vision over days. These may indicate that dry AMD has converted to wet AMD and require same-day evaluation.
Home monitoring: If you have intermediate or advanced dry AMD, daily Amsler grid testing (a simple grid of straight lines) can help you detect early changes. Test each eye separately, wearing your reading glasses, at a comfortable reading distance. If lines appear wavy, bent, or if new blank spots appear, call your retina specialist immediately.
Causes and Risk Factors
AMD develops through a combination of aging, genetics, and environmental factors. Drusen accumulate between the RPE and Bruch’s membrane, triggering chronic inflammation and oxidative stress that progressively damage the macula.
Non-modifiable risk factors:
- Age: The dominant risk factor. AMD is rare before 55 and affects approximately 30% of adults over 75.
- Genetics: Family history significantly increases risk. The strongest genetic associations are with the CFH and ARMS2/HTRA1 genes.
- Race: AMD disproportionately affects White/European-ancestry populations. Black Americans have the lowest prevalence of late AMD.
- Sex: Women have higher lifetime prevalence, partly due to longer lifespan.
Modifiable risk factors:
- Smoking: The strongest modifiable risk factor. Current smokers are 2–4 times more likely to develop AMD.
- Diet: A Mediterranean diet rich in leafy greens (lutein and zeaxanthin sources) is associated with lower AMD risk.
- Cardiovascular health: Hypertension, obesity, and physical inactivity are associated with increased AMD risk.
- AREDS2 supplementation: For patients with intermediate AMD, the AREDS2 formula reduces the risk of progressing to advanced AMD by approximately 25%.
How Is AMD Diagnosed?
AMD is an imaging-intensive disease. At Retina Vision Consultants, we use multiple complementary technologies to stage your condition, detect changes early, and guide treatment decisions.
- Dilated Fundus Examination: Your retina specialist evaluates drusen size and distribution, pigment changes, signs of fluid or bleeding (wet AMD), and areas of atrophy.
- Optical Coherence Tomography (OCT): The most important imaging tool in AMD care. OCT produces high-resolution cross-sectional images that reveal drusen, fluid (the hallmark of active wet AMD), geographic atrophy, and pigment epithelial detachments. OCT is performed at virtually every visit and can detect fluid before you notice vision changes.
- Fundus Autofluorescence (FAF): Maps RPE health and is the primary tool for tracking geographic atrophy progression. FAF is used to measure lesion size and monitor treatment response for the new GA therapies.
- OCT-Angiography (OCTA): A dye-free technique that detects abnormal blood vessel growth (choroidal neovascularization) by imaging blood flow, supplementing or sometimes replacing traditional angiography.
- Fluorescein Angiography (FA): A dye-based test that visualizes retinal blood vessels and confirms wet AMD by showing leakage patterns. Used when the diagnosis needs definitive confirmation.
- ForeseeHome Monitoring Device: An FDA-cleared home monitoring device for patients with intermediate dry AMD at risk of conversion to wet AMD. In clinical studies, 94% of patients using ForeseeHome who converted to wet AMD maintained 20/40 or better vision at detection, compared to only 62% using standard office visits alone. ForeseeHome is covered by Medicare.
Treatment Options at RVC
Treatment depends on the type and stage of your AMD. While there is no cure, effective treatments exist at every stage — and early detection consistently produces the best outcomes.
AREDS2 Vitamin Supplementation (For Intermediate Dry AMD)
The AREDS2 formula — containing lutein 10 mg, zeaxanthin 2 mg, vitamin C 500 mg, vitamin E 400 IU, zinc 80 mg, and copper 2 mg — is clinically proven to reduce the risk of progressing to advanced AMD by approximately 25% over 5 years. AREDS2 is recommended specifically for patients with intermediate AMD or advanced AMD in one eye. It is not recommended for early AMD. Patients should use the AREDS2 formulation (not the original formula, which contained beta-carotene that increased lung cancer risk in smokers).
Complement Inhibitors (For Geographic Atrophy)
In 2023, two treatments became the first ever approved for geographic atrophy — a historic milestone for dry AMD. Pegcetacoplan (Syfovre) and avacincaptad pegol (Izervay) are intravitreal injections that target the complement system to slow the rate of GA expansion by approximately 14–28% depending on the treatment and timepoint. They cannot restore lost vision, but they slow a disease that previously had no treatment. Earlier initiation appears to provide greater benefit over time.
Anti-VEGF Injections (For Wet AMD)
Anti-VEGF therapy transformed wet AMD from an untreatable blinding disease into one where most patients maintain vision. These injections block vascular endothelial growth factor (VEGF), the protein that drives abnormal blood vessel growth and fluid leakage. Current agents include Eylea®, Vabysmo®, Lucentis®, Avastin®, and Eylea HD®. In clinical trials, 90–95% of treated patients maintain vision, and 30–40% gain significant improvement. Treatment typically begins with monthly injections, then transitions to longer intervals (up to every 4 months with some agents) as your eye responds. Treatment continues indefinitely — wet AMD requires ongoing monitoring and most patients need ongoing injections.
Photobiomodulation (PBM) Therapy (For Intermediate Dry AMD)
PBM uses specific wavelengths of light to stimulate cellular function in the RPE. The LIGHTSITE III trial demonstrated a mean gain of 5.6 letters at 24 months, sustained at 3.7 years. PBM has received FDA approval for AMD treatment. It is non-invasive, requires no injections, and is positioned as a potential adjunct for patients with intermediate dry AMD.
Living With AMD: What to Expect
Will I go blind? AMD rarely causes total blindness. Peripheral vision is preserved in all forms and stages, meaning you can still walk through a room, navigate your environment, and maintain basic independence. However, central vision loss from AMD can significantly affect reading, driving, and recognizing faces.
The outlook varies by stage. Early and intermediate AMD progress slowly, and most patients retain functional vision for years with monitoring and AREDS2 supplementation. Geographic atrophy causes gradual but permanent central vision loss that the new treatments can slow but not reverse. Wet AMD can cause rapid vision loss if untreated, but the majority of treated patients maintain or improve their vision.
How often will I need to be seen? Early AMD requires annual exams. Intermediate AMD requires visits every 6–12 months with daily Amsler grid testing at home. Patients on treatment for geographic atrophy or wet AMD are seen approximately monthly during active treatment, with intervals extending as the condition stabilizes.
Your other eye matters. If you have late AMD in one eye, the fellow eye carries a substantial risk — approximately 24% of patients with wet AMD in one eye develop it in the other within two years. Both eyes are monitored at every visit.
When to See a Retina Specialist
If you are over 50, you should have a dilated eye exam at least every year. If you have been diagnosed with AMD, regular monitoring by a retina specialist is essential because the condition can progress or convert to wet AMD without warning.
If you notice sudden distortion, wavy lines, a new dark spot, or rapid blurring in your central vision, call Retina Vision Consultants immediately at (310) 269-8565 to request a same-day appointment. Early intervention is the single most important factor in preserving your vision.
